<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584841</url>
  </required_header>
  <id_info>
    <org_study_id>2015/04MAI/231</org_study_id>
    <nct_id>NCT03584841</nct_id>
  </id_info>
  <brief_title>Implementation of a Non-invasive Version of the Imaging β-adrenergic-dependent Sweat Secretion Test</brief_title>
  <acronym>BUBBLE TEST</acronym>
  <official_title>Implementation of a Non-invasive Version of the Imaging β-adrenergic-dependent Sweat Secretion Test: Value for Diagnosis and Efficacy of Target Therapies for Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to implement a non-invasive version of the sweat secretion test
      based in visualization of sweat glands following β-adrenergic stimulation of sweat.
      Specifically, the trial will evaluate the relative response of sweat glands to β-adrenergic
      and cholinergic stimulation among participants with CF, heterozygous and matched control
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention Model: Three Group Assignment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio between the β-adrenergic/cholinergic rate</measure>
    <time_frame>up to 30 minutes</time_frame>
    <description>The ratio between the β-adrenergic/cholinergic rate (nL/min) of droplets of sweat is calculated.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mucoviscidosis Involving the Lung</condition>
  <arm_group>
    <arm_group_label>Patients with mucoviscidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients with cystic fibrosis: clinically stable, all genotypes included.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parents of patients with confirmed diagnosis of mucoviscidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The parents are heterozygous subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Iontophoresis sessions in forearm of subjects with pilocarpine</intervention_name>
    <description>The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Parents of patients with confirmed diagnosis of mucoviscidosis</arm_group_label>
    <arm_group_label>Patients with mucoviscidosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For patients with cystic fibrosis: clinically stable, all genotypes included.

          -  For healthy volunteer and heterozygous subjects: 18 years and older.

        Exclusion Criteria:

          -  Corticosteroids, anti-leukotriene therapy, unstable clinical status, &lt;40% FEV1.

          -  Current pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Teresinha LEAL, Biologist</last_name>
    <phone>00 32 2 764</phone>
    <phone_ext>94 73</phone_ext>
    <email>teresinha.leal@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audrey REYNAERTS, Sciences</last_name>
    <phone>00 32 2 764</phone>
    <phone_ext>94 72</phone_ext>
    <email>audrey.reynaerts@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresinha LEAL, Biologist</last_name>
      <phone>00 32 2 764</phone>
      <phone_ext>9473</phone_ext>
      <email>teresinha.leal@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Audrey REYNAERTS</last_name>
      <phone>00 32 2 764</phone>
      <phone_ext>9472</phone_ext>
      <email>audrey.reynaerts@uclouvain.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>There is no plan now</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

